At the news
? BULLISHIMPACT 5/10 PRESS-RELEASE filed Jun 1, 2026 at 07:01 ET
Invivyd completed enrollment in the Phase 3 DECLARATION trial evaluating VYD2311 for prevention of symptomatic COVID-19. Top-line results are expected in late Q3 2026. The trial was upsized by ~500 subjects to enhance statistical power.
- Enrollment completed in DECLARATION trial evaluating VYD2311 for COVID-19 prevention.
- Trial is BLA-enabling, Phase 3, randomized, placebo-controlled with ~2,400 participants.
- Sample size re-estimation added ~500 subjects to enhance statistical power.
- Top-line results expected approximately late Q3 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access